When LGG patients in the CGGA dataset were classified into 4 groups according to the WHO grade and IDH1 mutation status, the expression levels of PSAT1 were highest in the group of grade II gliomas with IDH1 mutations, which was supposed to be the group with the best prognosis in LGGs (Figure 4E). This evidence concerns the gene PSAT1 and central nervous system cancer.